FATE Q4 2021 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+7.4% YoY

Gross Profit

-$52M-307.3% margin

Operating Income

-$69M-406.5% margin

Net Income

-$69M-402.0% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+20.0%

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$89M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$921M

Total Liabilities

$243M

Stockholders' Equity

$679M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$16M	+7.4%
Gross Profit	-$52M	-$23M	-127.2%
Operating Income	-$69M	-$33M	-107.7%
Net Income	-$69M	-$53M	-29.2%